University of Minnesota. Driven to Discover.
Discovery of the first new botulinum toxin in 40 years is coupled with withholding key data for security reasons.
Clinical trials will test a candidate vaccine for H7N9 flu in varying doses, some with immune boosters.
The tests could be used for detection and to help in drug development.
A new molecular strategy could diffuse some of the controversy over lab-modified flu viruses.
Experts say some properties of H7 viruses may lend themselves to human adaptation.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.